Patients Should Be Considered When Choosing a Vector Production Method

Viral vector production costs have a disproportionate influence on gene therapy prices, so choosing the virus manufacturing method that fits the product and its intended patient population is critical.

That is the view of researchers at Thermo Fisher Scientific, who examined the economics of gene therapy production in a study and concluded that choosing the right vector manufacturing platform is challenging.

“Optimal platform choice depends on indication prevalence, dose requirements, desired serotype flexibility, development timelines, and willingness to invest in process intensification,” study author Seyed Pouria Motevalian, PhD, writes.

Motevalian and co-authors compared three recombinant adeno-associated virus (rAAV) manufacturing methods—transient transfection, producer cell line approaches (PCLs), and baculovirus-based production—and found that the cost drivers for each differ markedly.

“On a per-batch basis, baculovirus infection is the most cost-efficient platform, followed by transient transfection and PCLs. However, when costs are normalized to vector titer, the ranking shifts, with transient transfection becoming the lowest-cost platform.

“Each platform has a distinct economic fingerprint: transient transfection is dominated by plasmids, transfection reagent, media, and endonuclease; PCL perfusion processes are driven by media and perfusion-related single-use hardware; and the baculovirus platform shifts a greater share of cost into downstream operations, particularly affinity capture,” Motevalian says.

Patient focus

With all this in mind, Motevalian and co-authors argue that, rather than focusing on material and reagent costs, developers must also factor in the needs of the target patient population when choosing how to produce viral vectors.

“Our analyses suggest there is no universally ‘best’ rAAV platform. Optimal platform choice depends on indication prevalence, dose requirements, desired serotype flexibility, development timelines, and willingness to invest in process intensification,” they say.

For example, for products intended for smaller populations, transient transfection, in which vector genes are introduced into producer cell lines, may be the best approach, despite the high cost of the DNA plasmids required.

In contrast, for mass market gene therapies, baculovirus infection or PCL-based vector manufacturing methods are a more cost-effective option, particularly in combination with optimized upstream and downstream processes.

Understanding these dynamics is critical for developers, according to the authors, who say gene therapy firms must factor them into process development as early as possible.

“Integrating quantitative cost modeling into platform selection and process development decisions early in program design will be essential for making rAAV therapies economically sustainable and expanding global patient access,” they say.

The post Patients Should Be Considered When Choosing a Vector Production Method appeared first on GEN - Genetic Engineering and Biotechnology News.